AOA Dx
ActiveBlood Test for Early Detection of Ovarian Cancer
About
AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.
AOA Dx is developing an AI-enabled, multi-omics blood test platform for early detection of cancer in women, with a focus on ovarian cancer. The offering combines lipidomics biomarkers with data science to provide early diagnostic insights. They position themselves as bringing innovative, cost-effective medical technologies from R&D to providers and patients.
AOA Dx provides a blood test platform that uses GlycoLocate™ and AKRIVIS GD™ technologies to detect early-stage ovarian cancer by leveraging AI and multi-omics data. The process involves a novel lipidomics-based biomarker approach combined with complementary biomarkers and data science to generate insights for early cancer diagnosis, delivered as a provider-accessible diagnostic tool.
Who it’s for: Healthcare providers and laboratories focused on women's health and early cancer detection, particularly those serving patients at risk for ovarian cancer.
- AI-enabled early detection
- Multi-omics biomarker analysis
- Lipidomics-based biomarkers
- Blood test workflow for providers
- Early-stage cancer detection insights
- Complementary biomarker integration
Hiring and career opportunities mentioned; emphasis on bringing technologies from R&D to providers and patients
Founders · 3
CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health.
Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health.
Formerly “AOA Dx Inc.”
Related startups
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
AI Agents for Oncology EHRs
